Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
This article was originally published in The Pink Sheet Daily
The deal also signals Merck's partnering strategy in emerging markets for its branded and innovative products, especially in Asia. The company expects EMs to contribute 25% of Merck's global sales by 2013.
You may also be interested in...
Simcere Acquires Manufacturing Rights For Generic Crestor In China; Hopes Sales Force Will Provide Edge Over Competition
SHANGHAI - Chinese firm Simcere signed an agreement with Tianjin Tianda Pharmaceutical to acquire the manufacturing license in China for Tianda's rosuvastatin, a generic version of AstraZeneca's cholesterol and atherosclerosis treatment Crestor (rosuvastatin), Simcere announced Nov. 9
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.